EUVIMEDEUVIMED entdecken
Crossref

A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy

Xing-Yu Cao iD, Jian-Ping Zhang, Yue Lu iD, Yan-Li Zhao, De-Yan Liu, Min Xiong, Rui-Juan Sun, Zhi-Jie Wei, Jia-Rui Zhou, Xian Zhang iD, Jun-Fang Yang, Jingjing Li und 1 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Xing-Yu Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hebei Yanda Lu Daopei Hospital, Langfang, China. Hauptthemen laut MEDLINE: Antigens, CD7, Hematopoietic Stem Cell Transplantation, Immunotherapy, Adoptive, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: S&T Program of Hebei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD7‐targeted chimeric antigen receptor T‐cell (CAR‐T) therapy has shown promising initial complete remission (CR) rates in patients with refractory or relapsed (r/r) T‐cell acute lymphoblastic leukaemia and lymphoblastic lymphoma (T‐ALL/LBL). To enhance the remission duration, consolidation with allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is considered. Our study delved into the outcomes of 34 patients with r/r T‐ALL/LBL who underwent allo‐HSCT after achieving CR with autologous CD7 CAR‐T therapy. These were compared with 124 consecutive T‐ALL/LBL patients who received allo‐HSCT in CR following chemotherapy. The study revealed that both the CAR‐T and chemotherapy cohorts exhibited comparable 2‐year overall survival (OS) (61.9% [95% CI, 44.1–78.1] vs. 67.6% [95% CI, 57.5–76.9], p = 0.210), leukaemia‐free survival (LFS) (62.3% [95% CI, 44.6–78.4] vs. 62.0% [95% CI, 51.8–71.7], p = 0.548), non‐relapse mortality (NRM) rates (32.0% [95% CI, 19.0–54.0] vs. 25.3% [95% CI, 17.9–35.8], p = 0.288) and relapse incidence rates (8.8% [95% CI, 3.0–26.0] vs. 15.8% [95% CI, 9.8–25.2], p = 0.557). Patients aged ≤14 in the CD7 CAR‐T group achieved high 2‐year OS and LFS rates of 87.5%. Our study indicates that CD7 CAR‐T therapy followed by allo‐HSCT is not only effective and safe for r/r T‐ALL/LBL patients but also on par with the outcomes of those achieving CR through chemotherapy, without increasing NRM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD7Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptivePrecursor T-Cell Lymphoblastic Leukemia-LymphomaRemission InductionAdolescentAdultChildChild, PreschoolFemaleHumansMaleMiddle AgedYoung AdultReceptors, Chimeric AntigenRecurrenceSurvival RateTransplantation, HomologousTreatment Outcome

Stichwörter der Autor:innen

CD7 CAR‐T therapyT‐ALLT‐LBLallogeneic haematopoietic stem cell transplantation

Substanzen

Antigens, CD7Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Beijing Lu Daopei Hospital, Beijing, China.
  • Beijing Lu Daopei Institute of Hematology, Beijing, China.

ORCID-Profile: Xing-Yu Cao, Yue Lu, Xian Zhang

Förderung

  • S&T Program of Hebei

Zitieren

APA

Cao, X. Y., Zhang, J. P., Lu, Y., Zhao, Y. L., Liu, D. Y., Xiong, M., Sun, R. J., Wei, Z. J., Zhou, J. R., Zhang, X., Yang, J. F., Li, J., & Lu, P. (2024). A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy. British Journal of Haematology. https://doi.org/10.1111/bjh.19445

Vancouver

Cao XY, Zhang JP, Lu Y, Zhao YL, Liu DY, Xiong M, et al. A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy. British Journal of Haematology. 2024. doi:10.1111/bjh.19445

BibTeX
@article{Cao2024,
  author = {Cao, Xing-Yu and Zhang, Jian-Ping and Lu, Yue and Zhao, Yan-Li and Liu, De-Yan and Xiong, Min and Sun, Rui-Juan and Wei, Zhi-Jie and Zhou, Jia-Rui and Zhang, Xian and Yang, Jun-Fang and Li, Jingjing and Lu, Peihua},
  title = {A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T‐cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T‐cell therapy},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19445}
}
Kostenlos starten →